Axsome Therapeutics, Inc.
Clinical trials sponsored by Axsome Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing central nervous system therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to keep night shift workers awake and safe Results expected Dec 2026 (estimated)
- New drug could curb binge eating episodes Results expected Dec 2026 (estimated)
-
Alzheimer's agitation drug safety trial ends early
Disease control Stopped earlyThis study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture…
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New depression drug shows promise but study halted early
Symptom relief Stopped earlyThis study looked at the long-term safety and symptom relief of an experimental drug called AXS-05 in 181 adults with treatment-resistant depression (depression that hasn't improved with other treatments). Participants took the drug and were monitored for side effects and mood ch…
Phase 2 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC